300639 Guangdong Hybribio Biotech
- 5.84
- -0.13-2.18%
Guangdong Hybribio Biotech News
Further Weakness as Guangdong Hybribio BiotechLtd (SZSE:300639) Drops 9.9% This Week, Taking Three-year Losses to 57%
Hybribio Biotech to Apply for 70 Million Yuan for Share Buyback Plan
Individual Investors Are Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥378m Last Week
Improved Revenues Required Before Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) Stock's 45% Jump Looks Justified
Strong Week for Guangdong Hybribio BiotechLtd (SZSE:300639) Shareholders Doesn't Alleviate Pain of Three-year Loss
Hybribio Biotech Unit Gets Nod to Trial Chloroquine Phosphate Gel
Guangdong Hybribio Biotech Unit Gets China Nod for HPV Diagnostic Kit
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Price Is Right But Growth Is Lacking After Shares Rocket 36%
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Guangdong Hybribio Biotech, Subsidiary Get Patent From Brazil for Isolation Method
Hybribio Calls for Raising International HPV Awareness
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System
The Total Return for Guangdong Hybribio BiotechLtd (SZSE:300639) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings Growth Rate Lags the 18% CAGR Delivered to Shareholders
Two Guangdong Hybribio Biotech Units Get Licenses From Drug Regulator
Guangdong Hybribio Biotech Registers Gene Testing Kit
Hybribio Showcased Cutting-edge Cervical Cancer HPV Diagnostic Solutions at ADLM 2023
No Data
